{"id":"mexenone","rwe":[{"pmid":"38723000","year":"2024","title":"Mexenone protects mice from LPS-induced sepsis by EC barrier stabilization.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"37749909","year":"2023","title":"Photopatch testing in Singapore: A 10-year retrospective study.","finding":"","journal":"Photodermatology, photoimmunology & photomedicine","studyType":"Clinical Study"},{"pmid":"33553934","year":"2021","title":"Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"23651271","year":"2013","title":"Photopatch testing in Asians: a 5-year experience in Singapore.","finding":"","journal":"Photodermatology, photoimmunology & photomedicine","studyType":"Clinical Study"},{"pmid":"16869867","year":"2006","title":"Causal agents of photoallergic contact dermatitis diagnosed in the national institute of dermatology of Colombia.","finding":"","journal":"Photodermatology, photoimmunology & photomedicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mexenon","offLabel":[],"synonyms":["mesenone","mexenone","mexenon"],"timeline":[],"approvals":[],"brandName":"Mexenon","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine Mexenon as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or blocking a disease-causing process. However, without more information on Mexenon's target and mechanism of action, it is difficult to provide a more detailed explanation.","oneSentence":"Mexenon is a small molecule modality that works by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"Mexenon's mechanism of action is not well understood, but it is believed to involve the modulation of a specific biological pathway or receptor. Further research is needed to fully elucidate its pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3359","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEXENONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:42:49.969886","biosimilars":[],"competitors":[],"genericName":"mexenone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005475","UNII":"ET1UGF4A0B","CHEBI":"CHEBI:134985","INN_ID":"1835","UMLSCUI":"C0066490","ChEMBL_ID":"CHEMBL1898387","PUBCHEM_CID":"71645","MESH_SUPPLEMENTAL_RECORD_UI":"C011031"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":13,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2024","pmid":"38723000","title":"Mexenone protects mice from LPS-induced sepsis by EC barrier stabilization.","journal":"PloS one"},{"date":"2023 Nov","pmid":"37749909","title":"Photopatch testing in Singapore: A 10-year retrospective study.","journal":"Photodermatology, photoimmunology & photomedicine"},{"date":"2021 Feb 2","pmid":"33553934","title":"Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1.","journal":"ACS omega"},{"date":"2013 Jun","pmid":"23651271","title":"Photopatch testing in Asians: a 5-year experience in Singapore.","journal":"Photodermatology, photoimmunology & photomedicine"},{"date":"2006 Aug","pmid":"16869867","title":"Causal agents of photoallergic contact dermatitis diagnosed in the national institute of dermatology of Colombia.","journal":"Photodermatology, photoimmunology & photomedicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mexenon (MEXENONE) is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Mexenon is unclear, and it is not known whether it is patented or available as a generic. Further information on Mexenon's pharmacokinetics, safety considerations, and clinical use is not available. As a result, Mexenon is not a recognized treatment option in the pharmaceutical industry.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}